Arvinas CSO automatic sale of 4,592 shares

Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic sale of common stock tied to tax withholding.

Rhea-AI Filing Summary

Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic sale of common stock tied to tax withholding. On February 13, 2026, 4,592 shares of common stock were sold in an open-market transaction at $11.89 per share to cover tax obligations from RSU vesting. After this transaction, Cacace directly owned 151,232 common shares, which include 1,576 shares previously acquired under the company’s 2018 Employee Stock Purchase Plan. The filing notes the sale did not represent a discretionary trade.

Insider Trade Summary

Net Seller: 4,592 shares

Net Sell 1 txn

Insider Cacace Angela M

Role Chief Scientific Officer

Sold 4,592 shs ($55K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,592	$11.89	$55K

Holdings After Transaction: Common Stock — 151,232 shares (Direct)

Footnotes (2)

1. F1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on February 13, 2025. The sale does not represent a discretionary trade.
2. F2. Includes an aggregate of 1,576 shares of common stock of the Issuer previously purchased under and in accordance with the 2018 Employee Stock Purchase Plan of the issuer in transactions exempt under Rule 16b-3.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARVINAS, INC. (ARVN) report for Angela M. Cacace?

Angela M. Cacace reported an automatic sale of 4,592 shares of Arvinas common stock. The shares were sold on February 13, 2026, in an open-market transaction at $11.89 per share to satisfy tax withholding from restricted stock unit vesting.

Was the ARVN insider stock sale by Angela M. Cacace discretionary?

The sale was not discretionary. It was made automatically by Arvinas to cover tax withholding obligations tied to the vesting and settlement of 25% of restricted stock units granted on February 13, 2025, according to the Form 4 footnote.

How many ARVN shares does Angela M. Cacace own after the reported transaction?

After the sale, Angela M. Cacace directly owned 151,232 shares of Arvinas common stock. This total includes 1,576 shares previously purchased under the company’s 2018 Employee Stock Purchase Plan in transactions exempt under Rule 16b-3.

What was the price per share in Angela M. Cacace’s ARVN stock sale?

The reported sale price was $11.89 per share for Arvinas common stock. This price applied to 4,592 shares sold in an open-market transaction executed to cover tax withholding obligations arising from restricted stock unit vesting.

What triggered the automatic sale of ARVN shares for Angela M. Cacace?

The automatic sale was triggered by the vesting and settlement of 25% of restricted stock units granted on February 13, 2025. Arvinas sold 4,592 shares on Angela M. Cacace’s behalf to satisfy associated tax withholding obligations.

Are any of Angela M. Cacace’s ARVN shares from an employee stock purchase plan?

Yes. Her reported holdings include 1,576 Arvinas common shares previously purchased under the 2018 Employee Stock Purchase Plan. These transactions were conducted in accordance with the plan and were exempt under Rule 16b-3, according to the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 06:13 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cacace Angela M

(Last) (First) (Middle)

C/O ARVINAS, INC.

5 SCIENCE PARK, 395 WINCHESTER AVE.

(Street)

NEW HAVEN CT 06511

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARVINAS, INC. [ ARVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		S		4,592(1)	D	$11.89	151,232(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on February 13, 2025. The sale does not represent a discretionary trade.

2. Includes an aggregate of 1,576 shares of common stock of the Issuer previously purchased under and in accordance with the 2018 Employee Stock Purchase Plan of the issuer in transactions exempt under Rule 16b-3.

Remarks:

	/s/ Jared Freedberg, as attorney-in-fact for Angela M. Cacace	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.